Panbela Therapeutics, Inc.
PBLA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $2 | $20 | $28 |
| - Cash | $3 | $1 | $12 | $9 |
| + Debt | $5 | $7 | $0 | $0 |
| Enterprise Value | $3 | $7 | $8 | $18 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$26 | -$36 | -$10 | -$6 |
| % Margin | – | – | – | – |
| EBITDA | -$51 | -$35 | -$11 | -$5 |
| % Margin | – | – | – | – |
| Net Income | -$25 | -$35 | -$10 | -$5 |
| % Margin | – | – | – | – |
| EPS Diluted | -232,429.55 | -40,748.57 | -20,773.7 | -14,798.1 |
| % Growth | -470.4% | -96.2% | -40.4% | – |
| Operating Cash Flow | -$25 | -$15 | -$7 | -$4 |
| Capital Expenditures | $0 | -$1 | $0 | $0 |
| Free Cash Flow | -$25 | -$16 | -$7 | -$4 |